In the phase 1 ASCEND-1 study, ceritinib demonstrated activity in ALK-rearranged locally advanced or metastatic cancer NSCLC patients, including both ALK-naïve and ALK-pretreated patients who had progressed following multiple lines of chemotherapy. This evidence concerns the gene ALK and metastatic malignant neoplasm.